Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Budde

Showing results (131-140 of 155) with videos related to

Pageof 16
Sort By:
Transplantation Proceedings|February 7, 2018
Late Steroid Withdrawal Following AB0-Incompatible Renal TransplantationF Bachmann, N Lachmann, K Budde, et al.
Transplantation|September 24, 2004
Quality of life of living kidney donors in Germany: a survey with the Validated Short Form-36 and Giessen Subjective Complaints List-24 questionnairesMarkus Giessing, Stefan Reuter, Bernd Schönberger, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|February 4, 2010
Sotrastaurin, a novel small molecule inhibiting protein kinase C: first clinical results in renal-transplant recipientsK Budde, C Sommerer, T Becker, et al.
Clinical Pharmacology and Therapeutics|March 30, 1999
Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipientsW Mück, I Mai, L Fritsche, et al.
European Journal of Clinical Pharmacology|January 26, 2012
Inosine monophosphate dehydrogenase activity in paediatrics: age-related regulation and response to mycophenolic acidA Rother, P Glander, E Vitt, et al.
Transplantation Proceedings|June 21, 2005
Laparoscopic versus open donor nephrectomy in Germany: impact on donor health-related quality of life and willingness to donateM Giessing, S Reuter, S Deger, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|October 26, 2006
FTY720 versus MMF with cyclosporine in de novo renal transplantation: a 1-year, randomized controlled trial in Europe and AustralasiaM Salvadori, K Budde, B Charpentier, et al.
Transplantation Proceedings|May 4, 2005
Graft function, cardiovascular risk factors, and sex hormones in renal transplant recipients on an immunosuppressive regimen of everolimus, reduced dose of cyclosporine, and basiliximabB K Krämer, H-H Neumayer, R Stahl, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|February 5, 2015
Evaluation of the effect of tofacitinib exposure on outcomes in kidney transplant patientsF Vincenti, H T Silva, S Busque, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|February 4, 2012
Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantationL Liefeldt, S Brakemeier, P Glander, et al.
Pageof 16

Showing results (131-140 of 155) with videos related to

Sort By:
Pageof 16
Transplantation Proceedings|February 7, 2018
Late Steroid Withdrawal Following AB0-Incompatible Renal TransplantationF Bachmann, N Lachmann, K Budde, et al.
Transplantation|September 24, 2004
Quality of life of living kidney donors in Germany: a survey with the Validated Short Form-36 and Giessen Subjective Complaints List-24 questionnairesMarkus Giessing, Stefan Reuter, Bernd Schönberger, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|February 4, 2010
Sotrastaurin, a novel small molecule inhibiting protein kinase C: first clinical results in renal-transplant recipientsK Budde, C Sommerer, T Becker, et al.
Clinical Pharmacology and Therapeutics|March 30, 1999
Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipientsW Mück, I Mai, L Fritsche, et al.
European Journal of Clinical Pharmacology|January 26, 2012
Inosine monophosphate dehydrogenase activity in paediatrics: age-related regulation and response to mycophenolic acidA Rother, P Glander, E Vitt, et al.
Transplantation Proceedings|June 21, 2005
Laparoscopic versus open donor nephrectomy in Germany: impact on donor health-related quality of life and willingness to donateM Giessing, S Reuter, S Deger, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|October 26, 2006
FTY720 versus MMF with cyclosporine in de novo renal transplantation: a 1-year, randomized controlled trial in Europe and AustralasiaM Salvadori, K Budde, B Charpentier, et al.
Transplantation Proceedings|May 4, 2005
Graft function, cardiovascular risk factors, and sex hormones in renal transplant recipients on an immunosuppressive regimen of everolimus, reduced dose of cyclosporine, and basiliximabB K Krämer, H-H Neumayer, R Stahl, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|February 5, 2015
Evaluation of the effect of tofacitinib exposure on outcomes in kidney transplant patientsF Vincenti, H T Silva, S Busque, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|February 4, 2012
Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantationL Liefeldt, S Brakemeier, P Glander, et al.
Pageof 16